It can also be used as a preventive measure against migraine in children and adolescents. In Australia this is the only indication for which cyproheptadine is subsidised by the PBS.
According to a small study, cyproheptadine hydrochloride has been found to improve sleep, calmness, and mood and energy levels, and to improve both negative and (sometimes even) positive psychotic symptoms in a subgroup of chronic schizophrenics who did not respond (either completely or sufficiently) to other therapies.
Cyproheptadine may improve akathisia in patients on antipsychotic medications.
In clinical trials in which cyproheptadine was used as an adjunct to antipsychotic treatment for patients with schizophrenia, an improvement in negative symptoms was seen.
Supportive measures such as gastric lavage or induced emesis are usually recommended in cases of overdose. The symptoms are usually indicative of CNS depression (or conversely CNS stimulation in some) and excess anticholinergic side effects. The LD50 in mice is 123 mg/kg and 295 mg/kg in rats.
Cyproheptadine is used in cats as an appetite stimulant and as an adjunct in the treatment of asthma. Possible adverse effects include excitement and aggressive behavior. The elimination half-life of cyproheptadine in cats is 12 hours.
Cyproheptadine has been used successfully in treatment of pituitary pars intermedia dysfunction in horses.
^ abGunja N, Collins M, Graudins A (2004). "A comparison of the pharmacokinetics of oral and sublingual cyproheptadine". Journal of Toxicology. Clinical Toxicology42 (1): 79–83. doi:10.1081/clt-120028749. PMID15083941.
^Taylor, D; Paton, C; Shitij, K (2012). Maudsley Prescribing Guidelines in Psychiatry (11th ed.). West Sussex: Wiley-Blackwell. ISBN978-0-47-097948-8.
^Silver, H; Blacker, M; Weller, MPI; Lerer, B (February 1989). "Treatment of chronic schizophrenia with cyproheptadine". Biological Psychiatry25 (4). doi:10.1016/0006-3223(89)90206-0.
^Rosskamp RH, Haverkamp F, von Kalckreuth G (May 1990). "The effect of cyproheptadine on plasma growth hormone (GH) and on somatostatin response to GH-releasing hormone in man". Horm. Metab. Res.22 (5): 295–7. doi:10.1055/s-2007-1004905. PMID1971804.
^Roth BL, Driscol J (12 January 2011). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 26 October 2013.